T-cell fighting cancer cell representing immunotherapy, with a faded figure struggling to breathe.

Nivolumab and Myasthenia Gravis: What You Need to Know About This Cancer Treatment's Unexpected Side Effect

Beau Callahan monogram
Beau Callahan in Health & Wellness October 2026 • 4 min read.

"A comprehensive look at nivolumab-induced myasthenia gravis, its symptoms, and what patients and caregivers should watch out for."


Nivolumab is an immunotherapy drug that has revolutionized the treatment of several aggressive cancers. By blocking the programmed cell death-1 (PD-1) receptor, it unleashes the immune system to fight cancer cells. While this approach has shown remarkable success, it also carries the risk of triggering immune-related adverse effects, one of which is myasthenia gravis (MG).

Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles, which are responsible for breathing and moving parts of the body. It occurs when the body's immune system mistakenly attacks the connections between nerves and muscles. Symptoms can vary widely, but often include drooping eyelids, double vision, difficulty swallowing, and fatigue. In severe cases, MG can lead to respiratory failure.

This article will explore a case of nivolumab-induced myasthenia gravis, shedding light on the importance of recognizing this potential side effect. We'll delve into the symptoms, diagnosis, and management of MG in the context of cancer immunotherapy, providing valuable information for patients, caregivers, and healthcare professionals.

AI Search Multiple angles on this topic

Source Material Does Not Address Nivolumab

The supplied sources discuss cellular PVC trim rather than nivolumab or myasthenia gravis. Boardway Building describes cellular PVC as manufactured through extrusion using PVC resin, foaming agents, and additives, producing a lightweight and moisture-resistant board. DG Floors similarly describes a foamed core with a density close to soft pine, while Elite Trimworks emphasizes warp-free and moisture-resistant performance. These sources provide no statistics about cancer treatment, neurological side effects, or patient impact.

Source Material Describes a Television Series

The supplied sources do not describe clinical approaches to nivolumab-associated myasthenia gravis. They describe Tell Me a Story, an American psychological thriller anthology series created by Kevin Williamson for CBS All Access. The sources characterize the series as a dark reimagining of beloved fairy tales, with storylines involving love, loss, greed, revenge, and murder. Consequently, they provide no evidence about accepted medical methods or their limitations.

Historical Context Requires Relevant Sources

A reliable historical account of nivolumab-associated myasthenia gravis would require sources addressing immunotherapy, neuromuscular disease, and clinical research. No such sources were provided for this subsection. Any specific timeline, milestone, or foundational discovery would therefore be unsupported by the supplied material.

Understanding Nivolumab and Its Mechanism of Action

T-cell fighting cancer cell representing immunotherapy, with a faded figure struggling to breathe.

Nivolumab is a type of immunotherapy called a checkpoint inhibitor. These drugs work by blocking certain proteins, called checkpoints, that prevent T cells (a type of immune cell) from attacking cancer cells. PD-1 is one such checkpoint found on T cells. By blocking PD-1, nivolumab allows T cells to recognize and kill cancer cells more effectively.

While nivolumab is effective against cancers like melanoma, non-small cell lung cancer, and renal cell carcinoma, its mechanism of action can also lead to unintended consequences. By revving up the immune system, nivolumab can sometimes cause it to attack healthy tissues, leading to autoimmune diseases. Myasthenia gravis is one such potential autoimmune side effect.

Here's a breakdown of the process:
  • Nivolumab binds to the PD-1 receptor on T cells.
  • This blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), which are often found on cancer cells.
  • By blocking this interaction, nivolumab prevents the cancer cell from deactivating the T cell.
  • The T cell remains active and is able to attack and kill the cancer cell.
AI Search Multiple angles on this topic

Source Material Covers K-Pop News

The supplied sources do not contain research or reviews about nivolumab or myasthenia gravis. They describe allkpop, which launched in October 2007 and presents itself as a source for K-pop celebrity gossip and news. The site states that it provides breaking news, gossip, and coverage of K-pop stars, including content associated with BTS. These materials offer no medical findings or treatment evidence.

Source Material Covers Australian Football

The supplied sources do not address counterarguments, treatment failures, or safety concerns involving nivolumab and myasthenia gravis. They concern Australian Football League standings and Sydney Swans coverage. AFL.com.au identifies ladder information such as games played, wins, draws, losses, points, and percentages. The Sydney Swans and Flashscore sources likewise provide football news, results, or standings rather than medical evidence.

No Comparative Medical Sources Provided

Comparative analysis of nivolumab-related myasthenia gravis would require relevant comparisons involving treatments, risks, outcomes, or patient groups. No sources addressing those subjects were supplied for this subsection. A specific comparison would therefore risk introducing claims not supported by the provided material.

The case study presented in the original article highlights this risk. A 73-year-old male with metastatic renal cell carcinoma developed myasthenia gravis after starting nivolumab treatment. He presented with fatigue and weakness, eventually progressing to respiratory failure. This case underscores the importance of vigilance and prompt recognition of MG symptoms in patients receiving nivolumab.

The Importance of Early Detection and Management

Nivolumab is a valuable tool in the fight against cancer, but it's crucial to be aware of its potential side effects. If you or a loved one is undergoing nivolumab treatment, be vigilant for symptoms of myasthenia gravis, such as muscle weakness, drooping eyelids, double vision, and difficulty swallowing or breathing. Early detection and prompt treatment can significantly improve outcomes and prevent severe complications.

AI Search Multiple angles on this topic

No Expert Medical Commentary Provided

The supplied material does not include expert commentary on nivolumab, immune-related neurological complications, or myasthenia gravis. Without a medical source, no evidence-based synthesis can be made about diagnosis, management, or prognosis. Any clinical interpretation would require additional authoritative sources.

Future Directions Cannot Be Established

The supplied sources do not discuss future research, emerging treatments, or next frontiers related to nivolumab-associated myasthenia gravis. No projections or research priorities can be responsibly identified from the material provided. Additional oncology and neurology sources would be needed for a supported outlook.

Systemic Context Is Not Covered

The supplied material does not address healthcare access, pharmacovigilance, diagnostic systems, or other systemic challenges involving nivolumab and myasthenia gravis. It therefore cannot support conclusions about broader clinical or public-health context. Such conclusions would require sources specifically focused on cancer care and neuromuscular disease.

Source Material Covers Chase Locations

The supplied sources do not describe patients' experiences with nivolumab or myasthenia gravis. They provide information about Chase branches and ATMs, including locations in McPherson Square, Washington, D.C., and Phillipsburg, New Jersey. The Chase search source also mentions financial advisors, financial strategies, and online investing. These details do not establish any medical or patient-impact information.

The case timeline and antibody result

  • 8.70 nmol/LThe AChR antibody result was 8.70 nmol/L, supporting the case report’s antibody-confirmed diagnosis.[1] [2]

What the reported case establishes

The reported course included fatigue and worsening limb weakness, followed by respiratory failure. It illustrates a serious possible presentation, not a typical course for everyone receiving the drug.[1] [2]

In this case, steroids and pyridostigmine were used, with pyridostigmine increased after its initial dose. A case report describes what happened to this patient; it does not compare treatment approaches or establish which approach is best.[1]

Where the case report is weakest

  • The authors found it difficult to judge treatment response because muscle disuse could also account for some weakness.[2]

A single-patient report of nivolumab-associated myasthenia gravis

DurationFour days of symptoms; nivolumab started two weeks before presenting complaints[2]
Times cited17[2]

The case alongside broader safety evidence

A separate report of nivolumab-treated cancer patients recorded 12 MG cases among 9,869 patients, while none were recorded among 408 treated with ipilimumab. These figures give a broader treatment-group context, but do not resolve causation in the individual case.[3]

A review of new-onset MG after PD-1 inhibitors found that some reported patients developed respiratory failure requiring intubation, and some died. Its pooled case evidence describes serious outcomes beyond this single report, not an individual risk estimate for every patient.[4]

Questions the case leaves unresolved

  • How often does nivolumab-associated MG occur across treated populations, given the case report’s call for surveillance and the separate treatment-group count?[2] [3]
  • Can clinicians distinguish newly triggered MG from a cancer-associated condition unmasked after treatment begins?[2]
  • How does antibody status relate to the range of presentations described in later work, including cases with concurrent muscle inflammation?[2] [5]

Questions about the evidence

How sensitive are AChR antibodies for confirming MG?

The case report states that AChR antibodies have sensitivity of up to 90%; it also notes that some AChR-negative patients have MuSK antibodies.[2]

Sources

  1. Myasthenia Gravis Induced by Nivolumab: A Case Report (Europe PMC, 2017)
  2. Myasthenia Gravis Induced by Nivolumab: A Case Report (Springer Science and Business Media LLC, 2017)
  3. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. (doi.org)
  4. Myasthenia gravis induced or exacerbated by immune checkpoint inhibitors: a rising concern (BMJ Case Reports, 2021)
  5. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.7759/cureus.1702, Alternate LINK

Title: Myasthenia Gravis Induced By Nivolumab: A Case Report

Subject: Aerospace Engineering

Journal: Cureus

Publisher: Cureus, Inc.

Authors: Jeet J Mehta, Eamon Maloney, Sachin Srinivasan, Patrick Seitz, Michael Cannon

Published: 2017-09-20

Everything You Need To Know

1

How does Nivolumab work to fight cancer, and what is the role of the PD-1 receptor in this process?

Nivolumab is an immunotherapy medication known as a checkpoint inhibitor. It functions by obstructing the programmed cell death-1 (PD-1) receptor found on T cells. This blockade prevents the PD-1 receptor from interacting with its ligands, PD-L1 and PD-L2, which are frequently present on cancer cells. By disrupting this interaction, Nivolumab prevents the cancer cells from deactivating T cells, enabling the T cells to remain active and target and eliminate cancer cells more effectively.

2

What is Myasthenia gravis (MG), and what are the common symptoms that patients and caregivers should be aware of?

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular condition marked by skeletal muscle weakness. This weakness arises when the immune system mistakenly attacks the connections between nerves and muscles. Key symptoms include drooping eyelids, double vision, difficulty swallowing, and fatigue. In severe instances, Myasthenia gravis can lead to respiratory failure, highlighting the importance of early detection and management.

3

What is the connection between Nivolumab treatment and the development of Myasthenia gravis (MG), and why does this side effect occur?

While Nivolumab is an effective cancer treatment, it can induce immune-related adverse effects, including Myasthenia gravis (MG). Nivolumab's mechanism, which involves enhancing the immune system, can lead to the immune system attacking healthy tissues, resulting in autoimmune conditions like Myasthenia gravis. Therefore, vigilance for symptoms such as muscle weakness, drooping eyelids, and double vision is essential for those undergoing Nivolumab treatment.

4

Why is early detection and management of Myasthenia gravis (MG) so important for patients undergoing Nivolumab treatment?

Early detection of Myasthenia gravis (MG) symptoms is critical for improving outcomes in patients undergoing Nivolumab treatment. Symptoms such as muscle weakness, drooping eyelids, double vision, and difficulty swallowing or breathing should be promptly reported. Early diagnosis and management can prevent severe complications like respiratory failure and significantly enhance the patient's quality of life. The 73-year-old male with metastatic renal cell carcinoma developed Myasthenia gravis after starting Nivolumab treatment as described, highlights the importance of vigilance.

5

What are the potential implications of Nivolumab's mechanism of action, specifically regarding the balance between anti-cancer immunity and autoimmune reactions?

Nivolumab's mechanism of action, which involves blocking the PD-1 receptor on T cells to enhance the immune system's ability to fight cancer cells, can have unintended consequences. While this blockade prevents cancer cells from deactivating T cells, it can also lead to the immune system attacking healthy tissues, resulting in autoimmune diseases like Myasthenia gravis (MG). This underscores the delicate balance between enhancing anti-cancer immunity and the risk of triggering autoimmune reactions, necessitating careful monitoring and management of patients receiving Nivolumab.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.